Athersys, Inc.  

(Public, NASDAQ:ATHX)   Watch this stock  
Find more results for Harrington Campbell
2.13
-0.04 (-1.84%)
Real-time:   9:30AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.13 - 2.13
52 week 0.94 - 2.90
Open 2.13
Vol / Avg. 0.00/685,336.00
Mkt cap 181.37M
P/E 234.07
Div/yield     -
EPS 0.01
Shares 84.36M
Beta 0.17
Inst. own 25%
Aug 9, 2016
Q2 2016 Athersys Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 9, 2016
Q2 2016 Athersys Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 23, 2016
Athersys Inc Annual Shareholders Meeting (Estimated)
Jun 20, 2016
Athersys Inc Annual Shareholders Meeting
Jun 8, 2016
Athersys Inc at Biotechnology Industry Organization (BIO) International Convention
May 5, 2016
Q1 2016 Athersys Inc Earnings Call
May 5, 2016
Q1 2016 Athersys Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 30.73% -137.45%
Operating margin 43.42% -143.71%
EBITD margin - -141.48%
Return on average assets 65.57% -61.00%
Return on average equity 84.38% -80.86%
Employees 60 -
CDP Score - -

Address

3201 Carnegie Ave
CLEVELAND, OH 44115-2634
United States - Map
+1-216-4319900 (Phone)
+1-216-3619495 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

Officers and directors

Gil Van Bokkelen Ph.D. Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
William Lehmann Jr President, Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
John J. Harrington Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 47
Bio & Compensation  - Reuters
Robert J. Deans Ph.D. Executive Vice President - Regenerative Medicine
Age: 63
Bio & Compensation  - Reuters
Laura K. Campbell CPA Vice President - Finance
Age: 51
Bio & Compensation  - Reuters
Lee E. Babiss Ph.D. Lead Independent Director
Age: 59
Bio & Compensation  - Reuters
Ismail Kola Independent Director
Age: 59
Bio & Compensation  - Reuters
Lorin Jeffry Randall Independent Director
Age: 72
Bio & Compensation  - Reuters
Jack L. Wyszomierski Independent Director
Age: 59
Bio & Compensation  - Reuters